30 Nov

Analysts Lower Their Target Price for Ferrari

WRITTEN BY Jitendra Parashar

Ferrari stock

Ferrari stock (RACE) has fallen ~7.5% this month after falling 14.5% in October. The fourth-quarter broader market sell-off has affected the Italian luxury carmaker the most among automakers. RACE has outperformed legacy auto companies and the broader market for the last two years. In 2016 and 2017, the stock rose ~21% and 80.3%, respectively, attracting auto investors’ attention. In comparison (XLY), Tesla (TSLA), General Motors (GM), and Ford (F) rose 45.7%, 17.7%, and 3.0%, respectively, in 2017.

Analysts Lower Their Target Price for Ferrari

Analysts’ target for Ferrari falls

Of the 11 Reuters-surveyed analysts covering Ferrari, 45% recommend “buy,” and 55% recommend “hold.” About a month ago, 9% of analysts recommended “sell” for RACE. Their 12-month consensus target price for Ferrari stock is $140.03, which is 29.3% higher than its market price of $108.33 and implies potential despite the recent sell-off in Ferrari stock amid market turmoil. However, analysts’ target price has fallen from $145.52 a month ago.

Recent fundamental updates

In the third quarter, RACE’s adjusted earnings rose ~4% YoY (year-over-year), and its revenue rose 0.3% YoY with the help of an 11% YoY jump in its global shipments offset by currency movements. Its adjusted EBITDA margin expanded to 33.2% from 31.8% YoY and 31.9% sequentially. In the next part, we’ll look at analysts’ ratings for Harley-Davidson (HOG) stock this month.

Latest articles

Tesla (TSLA) stock short sellers seem to be getting exasperated. Notably, Tesla stock has been the short sellers’ favorite.

In the week that ended on November 15, natural gas prices fell 3.5% and settled at 2.688 per MMBtu (million British thermal units).

The Dow Jones Index (DIA) and S&P 500 (SPY) are trading at record highs and on Friday the Dow Jones crossed the 28,000 level for the first time.

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.